Anticancer Drugs Practice Questions

Q: Which of the following drugs are used in the treatment of multiple myeloma?

Bortezomib, Melphalan, Cyclophosphamide. Multiple myeloma is a plasma cell dyscrasia characterized by the malignant proliferation of plasma cells in the bone marrow. The management involves a combination of proteasome inhibitors, alkylating agents, immunomodulators, and steroids. **Why Option B is Correct:** * **Bortezomib:** A reversible inhibitor of the **26S proteasome**. It prevents the degradation of pro-apoptotic proteins, leading to apoptosis of malignant plasma cells. It is a cornerstone of modern myeloma therapy. * **Melphalan:** A nitrogen mustard **alkylating agent**. It has been a standard treatment for myeloma for decades, often used in high doses prior to autologous stem cell transplantation. * **Cyclophosphamide:** Another **alkylating agent** frequently used in combination regimens (e.g., CyBorD: Cyclophosphamide, Bortezomib, Dexamethasone) for patients who may not tolerate melphalan or as part of salvage therapy. **Why Other Options are Incorrect:** * **Hydroxyurea:** Primarily used in myeloproliferative neoplasms (like Polycythemia Vera) and Sickle Cell Anemia (to increase HbF). It is not a standard treatment for multiple myeloma. * **Ketoconazole:** An antifungal that also inhibits steroidogenesis. While used in Cushing’s syndrome or advanced prostate cancer (to reduce androgens), it has no role in treating multiple myeloma. **High-Yield Clinical Pearls for NEET-PG:** * **Bortezomib Side Effect:** Peripheral neuropathy is a major dose-limiting toxicity. * **Thalidomide/Lenalidomide:** These immunomodulators (IMiDs) are also first-line agents for myeloma. Remember: Thalidomide causes **phocomelia** (teratogenicity). * **Mnemonic for Myeloma Clinical Features:** **CRAB** (Calcium elevation, Renal insufficiency, Anemia, Bone lesions). * **Drug of Choice for Hypercalcemia in Myeloma:** IV Bisphosphonates (e.g., Zoledronic acid).

Q: Which of the following drugs is useful for the treatment of advanced prostate cancer?

Hydroxyurea. **Explanation:** **Correct Option: A. Hydroxyurea** Hydroxyurea is an antimetabolite that acts as a **Ribonucleotide Reductase inhibitor**, blocking the conversion of ribonucleotides to deoxyribonucleotides, thereby inhibiting DNA synthesis (S-phase specific). While hormonal therapies (like GnRH analogs and Anti-androgens) are the mainstays for advanced prostate cancer, Hydroxyurea is historically and clinically recognized as an alternative palliative treatment for **metastatic, hormone-refractory prostate cancer**. It helps in reducing tumor burden and managing symptoms when first-line therapies fail. **Incorrect Options:** * **B & D. Cisplatin and Carboplatin:** These are platinum compounds that cause DNA cross-linking. While they are "workhorse" drugs for many solid tumors (lung, ovary, bladder, and testicular cancers), they are not standard first-line or typical choices for prostate cancer, which is more responsive to hormonal manipulation and taxanes. * **C. Paclitaxel:** This is a taxane that stabilizes microtubules. While its cousin, **Docetaxel**, is the gold standard chemotherapy for metastatic castration-resistant prostate cancer (mCRPC), Paclitaxel itself is not the preferred agent for this specific malignancy. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Hydroxyurea:** Inhibits Ribonucleotide Reductase. * **Other uses of Hydroxyurea:** Myeloproliferative disorders (CML, Polycythemia Vera) and **Sickle Cell Anemia** (it increases HbF levels, preventing sickling). * **Side Effect:** Significant myelosuppression (dose-limiting) and cutaneous ulcers. * **Prostate Cancer Tip:** If the question asks for the "Drug of Choice" for metastatic prostate cancer, look for **GnRH agonists (Leuprolide)** or **Docetaxel**. Hydroxyurea is used in refractory cases.

Q: Axicabtagene ciloleucel is indicated for which of the following conditions?

Diffuse large B cell lymphoma. **Explanation:** **Axicabtagene ciloleucel (Yescarta)** is a pioneering **Chimeric Antigen Receptor (CAR) T-cell therapy**. It involves genetically engineering a patient’s own T-cells to express a receptor that targets the **CD19 antigen**, which is characteristically found on the surface of B-cells. 1. **Why Option C is Correct:** Axicabtagene ciloleucel is FDA-approved for the treatment of adult patients with **relapsed or refractory large B-cell lymphoma**, including **Diffuse Large B-Cell Lymphoma (DLBCL)**, primary mediastinal B-cell lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. By targeting CD19, the engineered T-cells directly identify and eliminate the malignant B-cells. 2. **Why Other Options are Incorrect:** * **Relapsed Myeloma:** While CAR-T therapies exist for Multiple Myeloma (e.g., **Idecabtagene vicleucel**), they typically target **BCMA** (B-cell maturation antigen), not CD19. * **T-cell Lymphoma:** Axicabtagene targets CD19, which is a B-cell marker. It is ineffective against T-cell malignancies. * **Small Cell Lung Cancer:** This is a solid tumor of epithelial origin; CAR-T therapies are currently primarily utilized for hematological malignancies. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Adoptive immunotherapy (CD19-directed CAR-T). * **Major Side Effects:** * **Cytokine Release Syndrome (CRS):** Managed with **Tocilizumab** (IL-6 inhibitor). * **ICANS:** Immune Effector Cell-Associated Neurotoxicity Syndrome. * **Other CAR-T drugs:** **Tisagenlecleucel** (indicated for DLBCL and B-cell ALL).

Q: Venoocclusive disease of the liver is caused by which of the following agents?

Both Cyclophosphamide and Melphalan. **Explanation:** **Sinusoidal Obstruction Syndrome (SOS)**, formerly known as **Veno-occlusive Disease (VOD)** of the liver, is a clinical syndrome characterized by hepatomegaly, jaundice, and fluid retention. It occurs due to toxic injury to the sinusoidal endothelial cells, leading to the occlusion of terminal hepatic venules. **Why the correct answer is C:** Both **Cyclophosphamide** and **Melphalan** are potent alkylating agents commonly used in high-dose conditioning regimens prior to Hematopoietic Stem Cell Transplantation (HSCT). * **Cyclophosphamide:** Its metabolite, acrolein, is primarily associated with hemorrhagic cystitis, but the drug is also a well-documented cause of hepatic VOD, especially when used in combination with total body irradiation. * **Melphalan:** High-dose melphalan is a standard treatment for Multiple Myeloma and is a recognized independent risk factor for the development of VOD. Since both drugs are implicated in the pathogenesis of this condition, Option C is the most accurate choice. **Analysis of incorrect options:** * **Option A & B:** While both are correct individually, they are incomplete. In the context of NEET-PG, when two drugs in the options are known to cause a specific side effect, the "Both" or "All of the above" option is the preferred answer. **High-Yield Clinical Pearls for NEET-PG:** 1. **Antidote for VOD:** **Defibrotide** is the drug of choice for treating severe hepatic veno-occlusive disease. 2. **Busulfan:** This is another high-yield alkylating agent frequently associated with VOD (often more so than cyclophosphamide). 3. **Acrolein Toxicity:** Remember that while acrolein causes VOD in the liver, it causes **hemorrhagic cystitis** in the bladder (prevented by **MESNA**). 4. **Other drugs causing VOD:** Azathioprine and 6-Thioguanine.

Q: Gemtuzumab acts against which antigen?

CD33. **Explanation:** **Gemtuzumab ozogamicin** is a humanized monoclonal antibody conjugated to a cytotoxic derivative of calicheamicin. 1. **Why CD33 is correct:** Gemtuzumab specifically targets the **CD33 antigen**, a transmembrane glycoprotein expressed on the surface of myeloid cells. It is found on the leukemic blasts of approximately 90% of patients with **Acute Myeloid Leukemia (AML)**. Once the drug binds to CD33, the complex is internalized, releasing calicheamicin, which causes double-stranded DNA breaks and subsequent cell death. 2. **Why other options are incorrect:** * **CD11a:** This is a subunit of LFA-1. The drug **Efalizumab** (previously used for psoriasis) targets CD11a. * **CD22:** This is expressed on B-cells. Drugs targeting CD22 include **Inotuzumab ozogamicin** (used in ALL) and **Moxetumonab pasudotox** (used in Hairy Cell Leukemia). * **CD45:** Known as Leukocyte Common Antigen (LCA), it is expressed on all hematopoietic cells. There are currently no standard monoclonal antibody therapies targeting CD45 in routine clinical use for AML. **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Gemtuzumab is primarily used for CD33-positive **Acute Myeloid Leukemia (AML)**. * **Black Box Warning:** It is associated with a high risk of **Hepatotoxicity**, specifically **Veno-Occlusive Disease (VOD)** or Sinusoidal Obstruction Syndrome. * **Suffix "ozogamicin":** Indicates the drug is an antibody-drug conjugate (ADC) linked to calicheamicin.

Q: Alkalinization of urine is done during the administration of which of the following chemotherapeutic drugs?

Methotrexate. **Explanation:** **Methotrexate (MTX)** is the correct answer because it is a weak acid that is primarily excreted by the kidneys. At high doses, MTX and its metabolite (7-OH-methotrexate) are poorly soluble in acidic urine, leading to the formation of crystals in the renal tubules (**crystalluria**). This can cause acute kidney injury (AKI) due to obstructive nephropathy. **Alkalinization of urine** (using Sodium Bicarbonate) increases the ionization of Methotrexate, significantly enhancing its solubility and renal clearance, thereby preventing nephrotoxicity. **Analysis of Incorrect Options:** * **Ara-C (Cytarabine):** Its dose-limiting toxicity is bone marrow suppression and cerebellar ataxia (at high doses). It does not require urinary alkalinization. * **Cisplatin:** It is highly nephrotoxic (causing ATN), but the prevention strategy involves **aggressive hydration** and the use of **Amifostine** (a cytoprotective agent) or osmotic diuresis (Mannitol), not alkalinization. * **Ifosfamide:** Along with Cyclophosphamide, it causes **hemorrhagic cystitis** due to the metabolite **Acrolein**. This is prevented by vigorous hydration and the administration of **MESNA**, which neutralizes acrolein in the bladder. **High-Yield Clinical Pearls for NEET-PG:** * **Leucovorin Rescue:** Folinic acid (Leucovorin) is used to "rescue" normal cells from MTX toxicity by bypassing the inhibited Dihydrofolate Reductase (DHFR) enzyme. * **Glucarpidase:** An enzyme used as an antidote for MTX toxicity in patients with renal failure. * **Drug Interactions:** NSAIDs, Penicillins, and Probenecid decrease MTX excretion by competing for organic anion transporters (OAT), increasing toxicity.

Q: Which of the following statements is true regarding methotrexate?

Causes thrombocytopenia.. Methotrexate (MTX) is a folate antimetabolite that acts as a competitive inhibitor of the enzyme dihydrofolate reductase (DHFR) [1]. This inhibition prevents the conversion of dihydrofolate to tetrahydrofolate, halting DNA synthesis and cell proliferation [1]. 1. Why Option C is Correct: Methotrexate is a potent myelosuppressant. It inhibits the rapidly dividing cells of the bone marrow, leading to a decrease in all cell lines (pancytopenia) [2]. Thrombocytopenia (low platelet count) is a common and dose-limiting adverse effect of MTX therapy [3]. 2. Why Other Options are Incorrect: * Option A: At low doses (used in RA or psoriasis), MTX has high oral bioavailability (>70%). Bioavailability only decreases at higher doses due to saturation of intestinal transporters. * Option B: MTX has potent anti-inflammatory effects. It increases extracellular adenosine levels, which interferes with the action of IL-1 and other pro-inflammatory cytokines (TNF-α, IL-6). * Option D: MTX is an established second-line therapy for Crohn’s disease, particularly for maintaining remission in patients who are steroid-dependent or resistant to thiopurines. High-Yield Clinical Pearls for NEET-PG: * Rescue Therapy: Leucovorin (Folinic acid) is used to "rescue" normal cells from MTX toxicity by bypassing the inhibited DHFR enzyme [1]. * Antidote for Toxicity: Glucarpidase can be used to rapidly reduce toxic plasma concentrations of MTX. * Monitoring: Always monitor Liver Function Tests (LFTs) as MTX can cause hepatic fibrosis/cirrhosis with long-term use. * Contraindication: It is highly teratogenic (Category X) and must be avoided in pregnancy.

Q: Ofatumumab is a monoclonal antibody against:

CD20. **Explanation:** **Ofatumumab** is a fully humanized monoclonal antibody that targets the **CD20** antigen. CD20 is a transmembrane protein expressed on the surface of B-lymphocytes, from the pre-B cell stage through mature B cells (but not on plasma cells). **Why Option C is Correct:** Ofatumumab binds to a unique epitope on the CD20 molecule (distinct from the binding site of Rituximab), encompassing both the small and large extracellular loops. This binding triggers B-cell lysis primarily through **Complement-Dependent Cytotoxicity (CDC)** and Antibody-Dependent Cellular Cytotoxicity (ADCC). It is clinically used in the treatment of Chronic Lymphocytic Leukemia (CLL) and Relapsing Multiple Sclerosis (RMS). **Why Other Options are Incorrect:** * **CD19 (Option A):** Targeted by drugs like **Blinatumomab** (a BiTE) and CAR-T cell therapies (e.g., Tisagenlecleucel). CD19 is a biomarker for B-cell lineage but is not the target for Ofatumumab. * **CD79a (Option B):** Part of the B-cell receptor complex. While used in immunohistochemistry to identify B-cell neoplasms, it is not a common target for current monoclonal antibody therapy in this context. * **CD25 (Option C):** This is the alpha chain of the IL-2 receptor. It is targeted by **Basiliximab** and **Daclizumab**, primarily used to prevent transplant rejection. **High-Yield Clinical Pearls for NEET-PG:** * **Anti-CD20 Trio:** Remember **Rituximab** (chimeric), **Ofatumumab** (fully human), and **Obinutuzumab** (type II, glycoengineered). * **Ofatumumab Advantage:** Being a fully human antibody, it has a lower risk of infusion-related reactions compared to the chimeric Rituximab. * **Key Indication:** It is a first-line subcutaneous B-cell depleting therapy for **Multiple Sclerosis**.

Q: Pulmonary fibrosis is associated with the use of which of the following drugs?

Bleomycin. **Explanation:** **Bleomycin** is a glycopeptide antibiotic used in cancer chemotherapy (e.g., Hodgkin lymphoma, testicular cancer) that acts by inducing DNA strand breaks through free radical generation. The most characteristic and dose-limiting toxicity of Bleomycin is **pulmonary fibrosis**. This occurs because the lungs lack the enzyme **bleomycin hydrolase**, which normally inactivates the drug. Consequently, the drug accumulates in lung tissue, leading to oxidative stress, cytokine release, and subsequent fibroblast proliferation. **Analysis of Incorrect Options:** * **Cisplatin:** Primarily known for its **nephrotoxicity** (prevented by aggressive hydration and amifostine) and severe **ototoxicity**. It is not typically associated with pulmonary fibrosis. * **Methotrexate:** An antimetabolite (DHFR inhibitor) whose chief toxicities include **myelosuppression**, mucositis, and hepatotoxicity. While it can cause acute pneumonitis, chronic fibrosis is classic for Bleomycin. * **Actinomycin D (Dactinomycin):** An antitumor antibiotic used mainly in pediatric tumors (Wilms tumor). Its major side effects are **bone marrow suppression** and alopecia. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** Patients on Bleomycin should undergo regular **Pulmonary Function Tests (PFTs)**; a decrease in DLCO (Diffusing capacity of the lungs for carbon monoxide) is an early sign of toxicity. * **Risk Factor:** High concentrations of inspired oxygen (FiO2) during surgery can exacerbate Bleomycin-induced lung injury. * **Other drugs causing Pulmonary Fibrosis:** Remember the mnemonic **"BAM"** — **B**leomycin, **A**miodarone, **M**ethysergide, and **B**usulfan.

Question 1

Which of the following drugs are used in the treatment of multiple myeloma?

Accepted Answer

Bortezomib, Melphalan, Cyclophosphamide

Answer

Bortezomib, Melphalan, Hydroxyurea

Answer

Hydroxyurea, Ketoconazole, Cyclophosphamide

Answer

Bortezomib, Hydroxyurea, Ketoconazole

Question 2

Which of the following drugs is useful for the treatment of advanced prostate cancer?

Accepted Answer

Hydroxyurea

Answer

Cisplatin

Answer

Paclitaxel

Answer

Carboplatin

Question 3

What is true about Azathioprine?

Accepted Answer

It selectively affects the differentiation of T cells

Answer

It has more antitumor effect than immunosuppressant effect

Answer

It is not a prodrug

Answer

It is a pyrimidine antimetabolite

Question 4

Axicabtagene ciloleucel is indicated for which of the following conditions?

Accepted Answer

Diffuse large B cell lymphoma

Answer

Relapsed myeloma

Answer

T cell lymphoma

Answer

Small cell lung cancer

Question 5

Venoocclusive disease of the liver is caused by which of the following agents?

Accepted Answer

Both Cyclophosphamide and Melphalan

Answer

Cyclophosphamide

Answer

Melphalan

Answer

None of the above

Question 6

Gemtuzumab acts against which antigen?

Accepted Answer

CD33

Answer

CD11a

Answer

CD22

Answer

CD45

Question 7

Alkalinization of urine is done during the administration of which of the following chemotherapeutic drugs?

Accepted Answer

Methotrexate

Answer

Ara-C

Answer

Cisplatin

Answer

Ifosfamide

Question 8

Which of the following statements is true regarding methotrexate?

Accepted Answer

Causes thrombocytopenia.

Answer

Oral bioavailability is 30-40%.

Answer

Does not interfere with the action of IL-1.

Answer

Not useful in Crohn's disease.

Question 9

Ofatumumab is a monoclonal antibody against:

Accepted Answer

CD20

Answer

CD19

Answer

CD79a

Answer

CD25

Question 10

Pulmonary fibrosis is associated with the use of which of the following drugs?

Accepted Answer

Bleomycin

Answer

Cisplatin

Answer

Methotrexate

Answer

Actinomycin D

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?